TGTX’s Unexpected Surge: What’s Next? – BOVNews

Nov 6, 2024 · The forward P/E ratio, which uses projected earnings for the next financial year, is 26.66. Additionally, the Price-to-Sales Ratio is 15.12, reflecting the market’s valuation of the …

95%
OFF

CGTX’s Unexpected Surge: What’s Next? – BOVNews

2 weeks from now

Dec 12, 2024 · CGTX Stock Performance and Moving Averages In recent trading, Cognition Therapeutics Inc (CGTX) stock price has shown some volatility, fluctuating 27.95% over the …

bovnews.com

$28.98
OFF

TDS’s Unexpected Surge: What’s Next? – BOVNews

2 weeks from now

Oct 26, 2024 · Telephone and Data Systems Inc (TDS) Stock Trading Recap On Friday, Telephone and Data Systems Inc (TDS) stock saw a modest uptick, ending the day at $28.98 …

bovnews.com

53%
OFF

TMC’s Unexpected Surge: What’s Next? – BOVNews

2 weeks from now

Dec 25, 2024 · On Tuesday, TMC the metals company Inc (TMC) stock saw a modest uptick, ending the day at $0.88 which represents a slight increase of $0.03 or 3.53% from the prior …

bovnews.com

22%
OFF

VIRX’s Unexpected Surge: What’s Next? – BOVNews

2 weeks from now

Jan 6, 2025 · On Friday, Viracta Therapeutics Inc (VIRX) stock saw a modest uptick, ending the day at $0.22 which represents a slight increase of $0.04 or 22.22% from the prior close of …

bovnews.com

$2.47
OFF

TSHA’s Unexpected Surge: What’s Next? – BOVNews

2 weeks from now

Nov 25, 2024 · Taysha Gene Therapies Inc (TSHA) Stock Trading Recap On Friday, Taysha Gene Therapies Inc (TSHA) stock saw a modest uptick, ending the day at $2.47 which …

bovnews.com

FAQs about TGTX’s Unexpected Surge: What’s Next? – BOVNews Coupon?

What happened to TG Therapeutics (tgtx) in Q2?

The drugmaker delivered a couple of surprises in Q2. Shares of TG Therapeutics ( TGTX -7.97%) were crashing 50.4% lower as of 11:12 a.m. ET on Tuesday. The huge sell-off came after the company announced its second-quarter results. Total net product revenue was $16 million in the second quarter. ...

Will TG Therapeutics win back investors?

If that doesn't occur, TG Therapeutics will need to win back investors the old-fashioned way: by growing its sales by leaps and bounds. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy. ...

Does TG therapeutics have a deal with neuraxpharm?

The other big news from TG Therapeutics was that it inked a deal with Neuraxpharm to commercialize Briumvi outside of the U.S. TG will receive more than $150 million in up-front and near-term milestone payments plus tiered double-digit royalties of up to 30%. The smartest strategy for a company is to underpromise and overdeliver. ...

What happened to TG Therapeutics' ukoniq (Umbralisib)?

Following the FDA’s decision to withdraw the regulatory nod granted to TGTX’s sole marketed drug Ukoniq (umbralisib) effective May 31, 2022, TG Therapeutics has no approved product in its portfolio. ...

Could a spike in VIX futures be a sign of a surge in demand?

One indication that the jump in the VIX might not be reflective of a commensurate surge in demand for hedges could be found in VIX futures, Tchir said. The front-month VIX futures contract didn't rise nearly as much as the VIX itself, calling into question the move in the index. Tchir ultimately zeroed in on a more likely culprit. ...

Did the Vix signal a crisis?

Instead of signaling widespread panic, the VIX's dalliance with crisis levels may have had more to do with a quirk in how the index is calculated, Wall Street strategists said. ...